Matinas BioPharma Announces Board & Officer Changes
Ticker: MTNB · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, officer-appointment, compensation
TL;DR
Matinas BioPharma shakes up leadership, files new board members and exec comp details.
AI Summary
Matinas BioPharma Holdings, Inc. announced on March 11, 2025, changes related to its board of directors and certain officers, including the departure of directors and the election of new ones. The company also disclosed compensatory arrangements for its officers. The filing also includes other events and financial statements/exhibits.
Why It Matters
Changes in board composition and officer appointments can signal shifts in company strategy, leadership, and future direction.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can indicate internal shifts that may impact future performance.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- March 11, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the departure of directors and the election of new directors, but specific names are not detailed in this summary section.
Were there any changes in executive officers?
Yes, the filing mentions the appointment of certain officers.
What type of compensatory arrangements were disclosed?
The filing notes the disclosure of compensatory arrangements for certain officers.
What is the primary business of Matinas BioPharma Holdings, Inc.?
Matinas BioPharma Holdings, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
In which state is Matinas BioPharma Holdings, Inc. incorporated?
Matinas BioPharma Holdings, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding Matinas BioPharma Holdings, Inc. (MTNB).